WAVEMAN · COMPANY

PRME · Prime Medicine, Inc.

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

PRME

Name: Prime Medicine, Inc. (PRME) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Prime Medicine, Inc.

PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001894562

SEC FILINGS☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

+55.3%

XBRL, annual

NET MARGIN

-4342.4%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

86 funds added or opened last quarter

more than 60% of Pharma & Biotech

REVENUE

+55.3% year over year

more than 80% of Pharma & Biotech

MARGIN

-4342.4% net margin

below 97% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

86 funds added or opened positions in the latest 13F quarter, of 189 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +17.6%

+17.6%12M

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows 86 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for Prime Medicine, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Alphabet Inc.

—

BUY

2025-08-01

1,500,000.0

$5.0M

NELSEN ROBERT

Director

BUY

2025-08-01

3,030,300.0

$10.0M

ARCH Venture Fund XII, L.P.

—

BUY

2025-08-01

3,030,300.0

$10.0M

GILLIS STEVEN

—

BUY

2025-08-01

3,030,300.0

$10.0M

Liu David R.

—

BUY

2025-06-30

21,000.0

$52.9K

51 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 46 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

Alphabet Inc.

16,562,498.0 sh

$61.1M

BlackRock, Inc.

9,602,041.0 sh

$35.4M

ARK Investment Management LLC

8,348,746.0 sh

$30.8M

STATE STREET CORP

7,576,460.0 sh

$28.0M

VANGUARD CAPITAL MANAGEMENT LLC

4,522,640.0 sh

$16.7M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

ARK Genomic Revolution ETF

$17.5M POSITION · AS OF 2026-04-30

1.4%

AXS Green Alpha ETF

$490.9K POSITION · AS OF 2026-03-31

1.1%

Jacob Discovery Fund

$184.8K POSITION · AS OF 2026-02-28

1.1%

Virtus Biotech Clinical Trials Etf

$238.6K POSITION · AS OF 2026-04-30

0.6%

Global X Genomics & Biotechnology ETF

$187.9K POSITION · AS OF 2026-02-28

0.4%

Ultra-Small Company Market Fund

$417.6K POSITION · AS OF 2026-03-31

0.3%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 3 registered trials, 3 still enrolling or running — a status change here is dated weeks before the press release

Not applicable

1 ACTIVE

Multi-phase

2 ACTIVE

What changed recently

A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson

2026-09-02 · Not Yet Recruiting → Recruiting

PHASE1,PHASE2

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$4.6M	$3.0M	$0	$0
OPERATING INCOME	$-208.3M	$-202.5M	$-204.8M	$-116.5M
NET INCOME	$-201.1M	$-195.9M	$-198.1M	$-121.8M
EPS (DILUTED)	-1.35	-1.65	-2.18	-4.19
OPERATING CASH FLOW	$-162.6M	$-122.9M	$-165.4M	$-131.8M
CASH	$63.0M	$182.5M	$41.6M	$187.6M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE